The company is exposed to risks related to suppliers, sourcing, and raw materials due to geopolitical instability, including the Ukraine-Russia conflict, which has caused volatility in energy markets and increased energy costs, particularly for energy-intensive manufacturing facilities. The pharmaceutical and biotech sector depends on complex supply chains with a significant proportion of imported intermediate products, Active Pharmaceutical Ingredients (APIs), and specialty chemicals. Trade policy measures such as tariffs, trade barriers, regulatory requirements, and export control restrictions may increase costs or delay the procurement of essential materials, adversely impacting operations and research and development projects. Geopolitical tensions and evolving sanctions can result in higher import and export costs, longer customs processing times, and increased administrative burdens, which are critical concerns for products with short shelf lives and clinical trial materials. Delays or disruptions in sourcing key components, including reagents, lab equipment, or specialized materials, could substantially hinder research and product development timelines.
Evotec Se's Comment on Supply Chain
The company is exposed to risks related to suppliers, sourcing, and raw materials due to geopolitical instability, including the Ukraine-Russia conflict, which has caused volatility in energy markets and increased energy costs, particularly for energy-intensive manufacturing facilities. The pharmaceutical and biotech sector depends on complex supply chains with a significant proportion of imported intermediate products, Active Pharmaceutical Ingredients (APIs), and specialty chemicals. Trade policy measures such as tariffs, trade barriers, regulatory requirements, and export control restrictions may increase costs or delay the procurement of essential materials, adversely impacting operations and research and development projects. Geopolitical tensions and evolving sanctions can result in higher import and export costs, longer customs processing times, and increased administrative burdens, which are critical concerns for products with short shelf lives and clinical trial materials. Delays or disruptions in sourcing key components, including reagents, lab equipment, or specialized materials, could substantially hinder research and product development timelines.
Sources:
Evotec Se's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Evotec Se’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
